SE8701921L - Ny farmaceutisk anvendning - Google Patents

Ny farmaceutisk anvendning

Info

Publication number
SE8701921L
SE8701921L SE8701921A SE8701921A SE8701921L SE 8701921 L SE8701921 L SE 8701921L SE 8701921 A SE8701921 A SE 8701921A SE 8701921 A SE8701921 A SE 8701921A SE 8701921 L SE8701921 L SE 8701921L
Authority
SE
Sweden
Prior art keywords
tissue
new pharmaceutical
pharmaceutical application
medicament
damage
Prior art date
Application number
SE8701921A
Other languages
English (en)
Swedish (sv)
Other versions
SE8701921D0 (sv
Inventor
Jr H Berger
C J Frangakis
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/862,057 external-priority patent/US4976959A/en
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of SE8701921D0 publication Critical patent/SE8701921D0/xx
Publication of SE8701921L publication Critical patent/SE8701921L/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE8701921A 1986-05-12 1987-05-11 Ny farmaceutisk anvendning SE8701921L (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86204686A 1986-05-12 1986-05-12
US06/862,057 US4976959A (en) 1986-05-12 1986-05-12 T-PA and SOD in limiting tissue damage

Publications (2)

Publication Number Publication Date
SE8701921D0 SE8701921D0 (sv) 1987-05-11
SE8701921L true SE8701921L (sv) 1987-11-13

Family

ID=27127662

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8701921A SE8701921L (sv) 1986-05-12 1987-05-11 Ny farmaceutisk anvendning

Country Status (13)

Country Link
JP (1) JPH0680015B2 (da)
AU (1) AU600724B2 (da)
BE (1) BE1001425A4 (da)
CH (1) CH672989A5 (da)
DE (1) DE3715662A1 (da)
DK (1) DK237187A (da)
FR (1) FR2600895B1 (da)
GB (1) GB2194886B (da)
IE (1) IE59895B1 (da)
LU (1) LU86875A1 (da)
NL (1) NL8701113A (da)
NZ (1) NZ220260A (da)
SE (1) SE8701921L (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0780784B2 (ja) * 1987-10-23 1995-08-30 宇部興産株式会社 微小循環障害に基づく心筋虚血傷害治療薬
NZ230808A (en) * 1988-10-24 1993-04-28 Squibb & Sons Inc Pharmaceutical compositions and combinations containing an angiotensin-converting enzyme inhibitor and a thrombolytic agent
DE4038563A1 (de) * 1990-12-04 1992-06-11 Gruenenthal Gmbh Verwendung von superoxiddismutasen zur prophylaxe und/oder behandlung von organversagen bei risikopatienten mit polytrauma
US5520912A (en) * 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
DE19518625C2 (de) * 1995-05-24 1997-08-07 Buescher Pebueso Beton Verfahren zum Abdichten von Betonrohren und ein für die Durchführung des Verfahrens geeignetes Betonrohr
US6921751B1 (en) 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
US7175679B2 (en) 2001-03-29 2007-02-13 Biotempt B.V. Oligopeptide treatment of NF-κB mediated inflammation
US6844315B2 (en) 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
US20030220258A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US8680059B2 (en) 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
EP1138692A1 (en) 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments of human chorionic gonadotropin (hcg) as immunoregulator
EP1300418A1 (en) 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
US7576174B2 (en) 2000-03-29 2009-08-18 Biotempt B.V. Compositions capable of reducing elevated blood urea concentration
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
US7786084B2 (en) 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US7501391B2 (en) 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US7517529B2 (en) 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
JP4846799B2 (ja) 2005-07-05 2011-12-28 バイオテンプト ベー．フェー． 腫瘍の治療
EP1864692A1 (en) 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
WO2011013668A1 (ja) * 2009-07-27 2011-02-03 国立大学法人新潟大学 虚血性イベントの治療用医薬品組成物
US8652476B2 (en) 2009-07-27 2014-02-18 Niigata University Pharmaceutical composition for treating ischemic events
US10617756B2 (en) 2017-01-05 2020-04-14 Shimojani, LLC Drug regimen for treatment of cerebral ischemia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8003402A (nl) * 1980-06-11 1982-01-04 Leuven Res & Dev Vzw Nieuwe plasminogeen-activator en farmaceutisch preparaat met trombolytische werking.
EP0112122B1 (en) * 1982-12-14 1991-08-28 South African Inventions Development Corporation Plasminogen activator
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
NO171344C (no) * 1985-05-28 1993-03-03 Wellcome Found Fremgangsmaate for fremstilling av farmasoeytiske preparater inneholdende vevsplasminogenaktivator
US4929444A (en) * 1985-05-28 1990-05-29 Burroughs Wellcome Co. Low pH pharmaceutical formulation containing t-PA
AU6334586A (en) * 1986-05-15 1987-12-01 Emory University Composition and method for treating a thrombus and embolus

Also Published As

Publication number Publication date
BE1001425A4 (fr) 1989-10-31
SE8701921D0 (sv) 1987-05-11
JPS6322026A (ja) 1988-01-29
FR2600895A1 (fr) 1988-01-08
GB8711058D0 (en) 1987-06-17
IE871210L (en) 1987-11-12
GB2194886A (en) 1988-03-23
LU86875A1 (fr) 1988-01-20
JPH0680015B2 (ja) 1994-10-12
CH672989A5 (da) 1990-01-31
AU7270487A (en) 1987-11-19
DE3715662A1 (de) 1987-11-19
NL8701113A (nl) 1987-12-01
DK237187A (da) 1987-11-13
IE59895B1 (en) 1994-04-20
FR2600895B1 (fr) 1993-12-24
NZ220260A (en) 1990-07-26
AU600724B2 (en) 1990-08-23
GB2194886B (en) 1990-04-25
DK237187D0 (da) 1987-05-11

Similar Documents

Publication Publication Date Title
SE8701921D0 (sv) Ny farmaceutisk anvendning
ATE172359T1 (de) Kalt-sterilisermittel mit verlängerter aktivät
FI922325A0 (fi) Oral sammansaettning foer botning av inflammatoriska tarmkanalsjukdomar.
DE60040345D1 (de) VERFAHREN ZUR HERSTELLUNG EINER REVERSIBEL INAKTIVEN, ANGESäUERTEN PLASMINZUSAMMENSETZUNG
DE3864020D1 (de) Anordnung zur beseitigung von aktiven mitteln, oertlich verwendet gegen feste tumoren.
DK463989A (da) Farmaceutisk virksom kombination
DE69535916D1 (de) Oberflächenlokalisierte Expression von Enzymen in gengesteuerter Prodrugtherapie
IS1565B (is) Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar
ES8800601A1 (es) Un procedimiento para preparar una formulacion farmaceutica liofilizada de activador de plasminogeno de tejidro (t-pa)
DK261490D0 (da) New pharmaceutical compound
DK0460062T3 (da) Huperzin A-analoger
DE3677395D1 (de) Pharmazeutische zusammensetzung aus guar-gummi und anderen antiacida zum schutz der oeso-gastro-duodenalen schleimhaut.
TW337997B (en) Pharmaceutical preparation containing plasminogen activators
HUP9801924A2 (hu) Nátrium/hidrogén-csere inhibitorokat és szív- és keringési zavarok kezelésére alkalmas hatóanyagokat tartalmazó gyógyszerkészítmény
AU3744889A (en) Variants of plasminogen activators and processes for their production
EP0199117A3 (en) New therapeutical use of phosphocreatine
SE9602644D0 (sv) New use
ES2000033A6 (es) Composicion de bitionol sulfoxido porcedimiento para su fabricacion y metodo de utilizacion de aquella
AR030647A1 (es) Composicion farmaceutica con actividad de agua especifica
DK1019037T3 (da) Lægemiddel indeholdende delta-aminolevulinsyre
ES2039194T3 (es) Un metodo de preparar una composicion farmaceutica tromboliticamente activa.
DK0499679T3 (da) Terapeutisk middel til diabetisk gangræn
KR890701732A (ko) 개량형 조직 플라스미노겐 활성화 인자
GR77250B (da)
EP0386240A4 (en) Novel polypeptide compounds